ADAMTS13 is a specialized enzyme in your blood whose sole job is to cut oversized strands of a sticky clotting protein called von Willebrand factor (VWF). When ADAMTS13 works properly, it keeps VWF trimmed to manageable sizes so platelets do not clump where they should not. When ADAMTS13 is severely deficient, whether from inherited mutations or an autoimmune attack, ultra-large VWF strings accumulate in small blood vessels, triggering a rare and potentially fatal clotting disorder called thrombotic thrombocytopenic purpura (TTP). The enzyme’s relevance, though, extends well beyond TTP, touching sepsis, COVID-19 complications, stroke, preeclampsia, and even heart failure.
What ADAMTS13 Actually Does
Von Willebrand factor is released by the cells lining your blood vessels, especially when those cells are activated by injury or inflammation. In its freshly secreted form, VWF exists as enormous multimers that are extraordinarily sticky for platelets. Under normal conditions this stickiness is useful: it helps seal wounds. But if the ultra-large multimers are not pruned, they attract platelets indiscriminately, forming tiny clots (microthrombi) throughout the body’s smallest vessels.
ADAMTS13 prevents that scenario. When blood flow stretches ultra-large VWF strings into an elongated shape, it exposes a specific site that ADAMTS13 recognizes and cuts. The shearing force of flowing blood is actually part of the system’s design: without it, the cleavage site stays hidden inside a folded region of VWF, and ADAMTS13 cannot reach it.1PubMed. Cleavage of ultra-large von Willebrand factor by ADAMTS-13 under flow conditions This means the enzyme is most active exactly where you need it, in the high-flow environment of small arteries and capillaries where unchecked VWF would do the most damage.
A Built-In Safety Lock
ADAMTS13 does not circulate in a constantly active state. It folds into a compact, “closed” shape in which its own tail wraps back and partially blocks its working parts. Specifically, domains at the tail end (called CUB domains) bind to a region near the enzyme’s active center (the spacer domain), reducing its cutting ability by roughly two and a half times compared with a version of the enzyme that lacks those tail domains.2PubMed Central. Conformational activation of ADAMTS13 Think of it as a safety lock that prevents ADAMTS13 from chewing through VWF unnecessarily.
The lock opens when ADAMTS13 encounters its target. When VWF itself engages the CUB domains, it pulls the enzyme into an “open” conformation, boosting activity to full strength. Electron microscopy images of the two states confirm the shift: the closed form looks compact, while the open form is visibly more extended.3PubMed Central. Conformational activation of ADAMTS13 The practical upshot is that ADAMTS13 only fires up in the presence of its substrate, keeping the system tightly regulated.
This design has a downside, though. When the enzyme opens up, the spacer domain that was previously tucked away becomes exposed. That exposed surface happens to be the primary target for autoantibodies in immune-mediated TTP, a detail that directly links the enzyme’s regulation to its vulnerability.
Congenital TTP and the Gene Behind It
Congenital TTP, also known as Upshaw-Schulman syndrome, results from inherited mutations in the ADAMTS13 gene. As of the most comprehensive review of the literature, at least 76 distinct mutations have been cataloged.4PubMed. ADAMTS13 mutations and polymorphisms in congenital thrombotic thrombocytopenic purpura These mutations are scattered across many parts of the gene, which means the enzyme can be broken in a variety of ways: some mutations cripple the catalytic machinery, others destabilize the protein so it gets cleared before it can do its job.
The disease is rare and typically shows up as episodes of dangerously low platelet counts and red blood cell destruction (because red cells shatter as they squeeze past microthrombi in tiny vessels). Many people with congenital TTP go years without a crisis and then are tipped into one by a trigger. In a retrospective analysis of 78 patients, infection and pregnancy were the two most common triggers for acute episodes.5Blood. Pregnancy-Related Outcomes in Patients with Congenital Thrombotic Thrombocytopenic Purpura: Post Hoc Analysis of a Retrospective Chart Review Study Because pregnancy naturally raises VWF levels, a person whose ADAMTS13 barely keeps up at baseline can be overwhelmed during gestation.
Immune-Mediated TTP
The acquired form of TTP is more common than the congenital one and is driven by autoantibodies that either block ADAMTS13’s activity or accelerate its removal from the bloodstream.6PubMed Central. Anti-ADAMTS13 Autoantibodies in Immune-Mediated Thrombotic Thrombocytopenic Purpura The result is the same: severe ADAMTS13 deficiency, unchecked ultra-large VWF, and widespread microvascular clotting.
Researchers have mapped where these antibodies latch onto ADAMTS13, and the answer is strikingly consistent across patients. In one study, all patient samples contained antibodies targeting the spacer domain, with a fragment containing the spacer recognized by every sample tested.7PubMed. The spacer domain of ADAMTS13 contains a major binding site for antibodies in patients with thrombotic thrombocytopenic purpura In another cohort, roughly 97 percent of patients harbored antibodies that bound a truncated version of ADAMTS13 ending at the spacer domain.8PubMed Central. Multiple domains of ADAMTS13 are targeted by autoantibodies against ADAMTS13 in patients with acquired idiopathic thrombotic thrombocytopenic purpura
The critical amino acid residues have been narrowed down to just a handful. Three residues on the spacer surface, designated R660, Y661, and Y665, form the core of the dominant antibody epitope. Replacing any of them with alanine reduces or abolishes antibody binding.9Blood. An autoantibody epitope comprising residues R660, Y661, and Y665 in the ADAMTS13 spacer domain identifies a binding site for the A2 domain of VWF These same residues are also involved in binding VWF, which explains why antibodies targeting them are so effective at neutralizing the enzyme: they block the very contact point ADAMTS13 uses to grab its substrate.10Journal of Thrombosis and Haemostasis. Humoral immune response to ADAMTS13 in acquired thrombotic thrombocytopenic purpura
How ADAMTS13 Deficiency Is Measured
The diagnostic threshold that separates TTP from other conditions causing microthrombi is an ADAMTS13 activity level below 10 percent of normal. That cutoff is not arbitrary: patients below it have a clinical profile distinct from those above it, including more frequent neurological problems and lower platelet counts.11PubMed. Correlation between ADAMTS13 activity and neurological impairment in acute thrombotic microangiopathy patients The severe deficiency label is widely used as the defining laboratory feature of TTP.12PubMed Central. The Highs and Lows of ADAMTS13 Activity
Getting that result quickly matters, because TTP is a medical emergency. Older enzyme-linked assays take about four hours; newer assays based on fluorescence principles can produce a result in under an hour, though they require specialized equipment.13PubMed. ADAMTS13 Activity Measurement by ELISA and Fluorescence Resonance Energy Transfer Assay In practice, many hospitals still start treatment for suspected TTP before the ADAMTS13 result comes back, because waiting could be fatal. The lab confirmation then guides whether to continue or redirect therapy.
Treatments Old and New
For decades, the standard treatment for immune TTP has been therapeutic plasma exchange (TPE): the patient’s plasma is physically removed and replaced with donor plasma, simultaneously diluting the autoantibodies and supplying functional ADAMTS13. TPE is effective but intensive, requiring large-bore intravenous access, specialized equipment, and often an ICU stay. Immunosuppressive drugs are added to shut down the autoimmune attack itself.
A newer drug, caplacizumab, takes a different approach. Rather than restoring ADAMTS13, it blocks the interaction between VWF and platelets directly, preventing microthrombi from forming while the immune suppression takes hold. Clinical experience shows it reduces clot-related events, deaths, relapse rates, and time spent in the hospital.14PubMed Central. Caplacizumab in adult patients with acquired thrombotic thrombocytopenic purpura Structurally, caplacizumab is a nanobody (a tiny antibody fragment) that binds the A1 domain of VWF. Its mechanism turns out to be more subtle than simple steric blocking: it locks VWF into a shape that platelets cannot adhere to properly, rather than physically occupying the platelet-binding site.15PubMed. High-resolution structure of the vWF A1 domain in complex with caplacizumab, the first nanobody-based medicine for treating acquired TTP
For congenital TTP, the most exciting recent development is recombinant ADAMTS13, a lab-made version of the missing enzyme. In a phase 3 trial, patients receiving prophylactic recombinant ADAMTS13 experienced no acute TTP events, while their mean peak enzyme activity reached about 101 percent of normal, compared with roughly 19 percent on standard plasma-based therapy. Drug-related side effects were also substantially lower.16PubMed. Recombinant ADAMTS13 in Congenital Thrombotic Thrombocytopenic Purpura A systematic review pooling two randomized trials did not find statistically significant differences in acute TTP events, partly because events were rare in both arms, but it did confirm that recombinant ADAMTS13 dramatically raised enzyme activity levels and was associated with fewer allergic reactions like urticaria.17Blood Coagulation & Fibrinolysis. Recombinant ADAMTS13 in thrombotic thrombocytopenic purpura: a systematic review and meta-analysis No patients developed neutralizing antibodies against the recombinant enzyme, which is an important concern whenever you give someone a protein their body has never made on its own.18PubMed. Recombinant ADAMTS13 in Congenital Thrombotic Thrombocytopenic Purpura
ADAMTS13 in Sepsis and Critical Illness
TTP is the disease most tightly linked to ADAMTS13 deficiency, but it is not the only one. In severe sepsis and disseminated intravascular coagulation (DIC), ADAMTS13 levels also drop substantially. The underlying reason is different: rather than autoantibodies destroying the enzyme, overwhelming inflammation both consumes ADAMTS13 (because there is so much activated VWF to process) and suppresses its production.19PubMed Central. VWF excess and ADAMTS13 deficiency: a unifying pathomechanism linking inflammation to thrombosis in DIC, malaria, and TTP
In pediatric sepsis, lower ADAMTS13 activity on the first day of admission correlates with more severe organ dysfunction and a higher risk of death.20PubMed Central. Decreased ADAMTS 13 Activity is Associated With Disease Severity and Outcome in Pediatric Severe Sepsis Children who progressed to septic shock had significantly lower ADAMTS13 than those with milder forms of sepsis. Similar patterns hold in a separate pediatric study, where lower ADAMTS13 was linked to need for mechanical ventilation, vasopressor use, and multiple organ dysfunction.21Egyptian Pediatric Association Gazette. ADAMTS13 in pediatric sepsis: a prognostic biomarker with potential therapeutic implications Whether supplementing ADAMTS13 in sepsis patients would improve outcomes is still an open question, but the association is strong enough to fuel ongoing interest.
The VWF-ADAMTS13 Imbalance in COVID-19
COVID-19 provided a dramatic natural experiment in VWF-ADAMTS13 dynamics. Patients with severe disease showed massively elevated VWF levels, sometimes several times above normal, while ADAMTS13 activity dropped as the disease worsened. In one study, median ADAMTS13 activity fell from about 82 percent in patients needing low-intensity care to roughly 55 percent in those needing high-intensity care.22PubMed Central. The ADAMTS13-von Willebrand factor axis in COVID-19 patients The ratio of VWF to ADAMTS13 therefore swung dramatically upward, creating a prothrombotic environment even though ADAMTS13 levels did not fall as low as they do in TTP.
A separate study of patients with severe COVID-19 found median ADAMTS13 activity of about 68 percent, alongside a marked loss of the largest VWF multimers in roughly three-quarters of patients.23Journal of Thrombosis and Haemostasis. Defective von Willebrand factor–ADAMTS13 axis multimer balance in severe COVID-19 That loss of large multimers likely reflects the enzyme working overtime but being outpaced by the flood of VWF from inflamed blood vessel walls. The VWF-ADAMTS13 imbalance helped explain why COVID-19 patients developed so many small-vessel blood clots, even in the lungs, kidneys, and brain.
ADAMTS13 and Cryptogenic Stroke
A small but provocative area of research involves strokes that have no obvious cause. In a single-center case series of nine patients with severe ADAMTS13 deficiency but no overt signs of TTP (no hemolysis, and normal platelet counts in most cases), eight of nine met criteria for embolic stroke of undetermined source before anyone thought to check ADAMTS13 levels. Four had large vessel occlusions, and three had strokes in multiple areas of the brain.24Elsevier / Journal of Stroke and Cerebrovascular Diseases. Severe ADAMTS-13 deficiency without hemolysis as a cause of cryptogenic stroke: A single center case series The implication is that ADAMTS13 deficiency can quietly cause strokes without triggering the full clinical picture of TTP, meaning the diagnosis gets missed unless the test is specifically ordered. This is very early-stage evidence, but it raises the question of whether ADAMTS13 testing should become part of the standard workup for unexplained strokes, at least in certain patient profiles.
Preeclampsia and the Placental Connection
Pregnancy itself raises VWF levels, and a healthy pregnancy already pushes the VWF-ADAMTS13 balance toward more clotting. In preeclampsia, that balance tips further. Women with preeclampsia have been found to have lower ADAMTS13 activity than women with uncomplicated pregnancies, combined with significantly higher VWF antigen levels, which together yield a markedly elevated VWF-to-ADAMTS13 ratio.25Journal of Thrombosis and Haemostasis. Alterations of the von Willebrand factor/ADAMTS13 axis in preeclampsia Another study found ADAMTS13 activity significantly lower in preeclampsia patients (median around 70 percent) alongside elevated markers of complement activation.26PubMed Central. Increased Complement Activation and Decreased ADAMTS13 Activity Are Associated with Genetic Susceptibility in Patients with Preeclampsia/HELLP Syndrome Compared to Healthy Pregnancies
This overlap is more than academic. Preeclampsia can occasionally progress to HELLP syndrome, which shares features with TTP (low platelets, red cell destruction, organ damage). Distinguishing the two conditions from each other is one of the harder diagnostic puzzles in obstetric medicine, and ADAMTS13 levels are one of the few lab tests that can help sort them out, since TTP drives the value far lower than preeclampsia typically does.
Beyond Clotting: Neutrophil Traps and Heart Failure
ADAMTS13’s influence appears to reach beyond platelet clumping. Neutrophils, a type of white blood cell, can release web-like structures made of DNA and enzymes called neutrophil extracellular traps (NETs). NETs are meant to snare bacteria, but when produced excessively they contribute to inflammation and clotting. Research using blood from immune TTP patients found that recombinant ADAMTS13 prevented NET accumulation under flow conditions, similar to what an enzyme that degrades DNA (DNase I) could achieve.27Blood Advances. Targeting neutrophil extracellular trap accumulation under flow in patients with immune-mediated thrombotic thrombocytopenic purpura The pathway appears to go through VWF: because ultra-large VWF strings recruit platelets, and activated platelets can trigger neutrophils to release NETs, keeping VWF trimmed indirectly dampens NET production.
In mice genetically engineered to lack ADAMTS13, NET levels and heart tissue infiltration by NETs increased significantly, and those animals developed worse cardiac dysfunction. Treating them with recombinant ADAMTS13 reversed the NET accumulation and improved cardiac function.28European Heart Journal. Von Willebrand factor exacerbates heart failure through formation of neutrophil extracellular traps This is still preclinical work, but it hints that the enzyme’s role in cardiovascular health extends well beyond its established niche of microvascular clotting disorders.
How Evolution Shaped the Enzyme
ADAMTS13 is not a recent evolutionary invention. Phylogenetic analysis across species shows that its allosteric regulation, the safety-lock mechanism described earlier, is broadly conserved. The tail-end domains responsible for that regulation (T7, T8, and the CUB domains) are essential and present across species, while the middle domains (T3 through T6) turn out to be dispensable for the regulation to work and vary more between species. Substrate specificity also varies: ADAMTS13 from one species does not always cut another species’ VWF efficiently.29Blood. Phylogenetic Analysis Identifies a Subset of ADAMTS13 Domains That Are Highly Conserved and Essential for Allosteric Regulation Separately, structure-function studies confirm that while the front half of ADAMTS13 handles the actual cutting of VWF, the back half contributes additional functions, including what appears to be an ability to break certain disulfide bonds in ultra-large VWF on the surface of activated blood vessel cells.30PubMed Central. Structure-function and regulation of ADAMTS-13 protease This dual functionality, both cutting and remodeling its substrate, is an unusual feature for a protease and may explain why the enzyme retained such a large and complex architecture over evolutionary time.